What is the recommended evaluation and management for thrombophilia?

Thrombophilia Evaluation and Management

Thrombophilia testing should NOT be performed routinely and is only indicated in highly selective scenarios where results will directly change clinical management—most commonly in unprovoked VTE in young patients, unusual-site thrombosis, or when family history suggests high-risk inherited thrombophilia that would alter contraceptive or pregnancy decisions. 1

When NOT to Test (Most Common Scenarios)

Do not test in the following situations 1, 2:

• Provoked VTE (surgery, trauma, immobilization, active cancer)
• During acute thrombosis or within the first 3 months of anticoagulation
• General population screening before starting combined oral contraceptives 1
• Arterial thrombosis (stroke, MI)
• Most patients with recurrent VTE already on indefinite anticoagulation

When Testing MAY Be Indicated

1. Unprovoked VTE in Specific Contexts

Test selectively when results would influence duration of anticoagulation 1:

• Age <50 years with first unprovoked VTE
• Unusual-site thrombosis (cerebral, splanchnic, mesenteric veins) where anticoagulation would otherwise be discontinued
• VTE associated with minor hormonal risk factors (oral contraceptives, pregnancy)

2. Family History Considerations

Test only when 1:

• First-degree relative with documented antithrombin, protein C, or protein S deficiency AND patient is considering:
  • Combined oral contraceptives or hormone replacement therapy
  • Pregnancy planning
  • Thromboprophylaxis decisions for minor provoking factors

3. Pregnancy-Related Scenarios

Test pregnant women only if 3:

• Family history of high-risk thrombophilia (antithrombin deficiency, homozygous Factor V Leiden, compound heterozygosity) AND results would change antepartum prophylaxis decisions
• Clinical criteria for antiphospholipid syndrome (≥3 pregnancy losses, prior VTE)

Do NOT test 4:

• Women with inherited thrombophilia and pregnancy complications for routine antithrombotic prophylaxis decisions
• Women with recurrent miscarriage without antiphospholipid antibodies or VTE history

4. Cancer-Associated Thrombosis

Consider testing only in 1:

• Low or intermediate-risk cancer patients with family history of VTE where results might influence prophylaxis intensity

What to Test (When Testing Is Indicated)

Complete thrombophilia panel includes 2, 5:

• Inherited: Factor V Leiden, Prothrombin G20210A mutation, antithrombin deficiency, protein C deficiency, protein S deficiency
• Acquired: Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin antibodies, anti-β2-glycoprotein-I antibodies)

Critical timing requirements 2, 6:

• NOT during acute thrombosis
• Wait ≥3 months after completing initial anticoagulation
• Protein C/S testing: avoid during acute phase or on warfarin (causes false-positive deficiency)
• Antithrombin: can test on heparin but not during acute clot
• Antiphospholipid antibodies: requires two positive tests ≥12 weeks apart

Management Based on Results

High-Risk Thrombophilias (Indefinite Anticoagulation Typically Warranted)

• Antithrombin deficiency with family history of VTE 7
• Homozygous Factor V Leiden 7
• Compound heterozygosity (Factor V Leiden + Prothrombin mutation)
• Triple-positive antiphospholipid syndrome

Pregnancy Management

Antepartum prophylaxis recommended for 4, 7:

• Antiphospholipid syndrome with ≥3 pregnancy losses: prophylactic/intermediate-dose UFH or prophylactic LMWH + aspirin 75-100 mg daily (Grade 1B)
• Antithrombin deficiency with family history of VTE: prophylactic LMWH (conditional recommendation)
• Homozygous Factor V Leiden or compound thrombophilia regardless of family history (conditional recommendation)

Do NOT use antepartum prophylaxis for 4:

• Inherited thrombophilia with pregnancy complications but no VTE history (Grade 2C)
• Heterozygous Factor V Leiden or Prothrombin mutation without family history of VTE 7

Postpartum prophylaxis (6 weeks minimum) 4, 3:

• ALL women with antepartum VTE: continue ≥6 weeks postpartum (minimum 3 months total) (Grade 2C)
• Antithrombin deficiency with family history: strongly recommended 7
• Protein C/S deficiency with family history: conditional recommendation 7

Preferred anticoagulant in pregnancy 4:

• LMWH over UFH for prevention and treatment (Grade 1B)
• LMWH over warfarin throughout all trimesters (Grade 1A first trimester, 1B second/third)
• Avoid DOACs (dabigatran, rivaroxaban, apixaban) completely (Grade 1C)

Contraceptive Counseling

If high-risk thrombophilia confirmed 1:

• Avoid estrogen-containing contraceptives
• Use progestin-only methods or non-hormonal options

Common Pitfalls to Avoid

1. Testing during anticoagulation: Warfarin falsely lowers protein C/S; DOACs interfere with most assays 2
2. Testing during acute illness: Inflammatory states alter protein levels 8
3. Overinterpreting heterozygous Factor V Leiden: Does NOT warrant indefinite anticoagulation after provoked VTE 1
4. Unnecessary testing costs and patient anxiety: 22% of tests change management; 78% do not 9
5. Testing asymptomatic family members: Only test if results change specific decisions (contraception, pregnancy prophylaxis) 2

The key principle: test only when a positive result will directly alter a specific management decision, not for general "information." 3, 1